PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
17962624-7	2008	AT1R blockade by candesartan abrogated CZ flow in WKY (0.58 mL/min/g), reduced myocardial superoxide, and blocked p38 and Akt activation.	candesartan	17-28	AKT serine/threonine kinase 1	Rattus norvegicus	122-125	
22357959-6	2012	Candesartan improved neurite outgrowth in the FDR, which was associated with the restoration of AT(2)R and phosphorylated Akt expression.	candesartan	0-11	AKT serine/threonine kinase 1	Rattus norvegicus	122-125	
22357959-10	2012	Candesartan improved AT(2)R neuronal function and Akt phosphorylation, which were associated with sensory nerve defects and insulin sensitivity in the FDR.	candesartan	0-11	AKT serine/threonine kinase 1	Rattus norvegicus	50-53	
22542793-8	2012	We identified the myocardial levels of phospho Akt and phosphoinositide 3-kinase, which are the upstream proteins of AMPK and MAPK activation and both were up-regulated in the vehicle-treated rats, whereas candesartan treatment significantly reversed these changes.	candesartan	206-217	AKT serine/threonine kinase 1	Rattus norvegicus	47-50	
21335466-7	2011	In contrast, dominant negative Akt (DN-Akt-Adv) reversed the beneficial effect of candesartan on CCG in JCR:LA-cp rats.	candesartan	82-93	AKT serine/threonine kinase 1	Rattus norvegicus	31-34	
21335466-7	2011	In contrast, dominant negative Akt (DN-Akt-Adv) reversed the beneficial effect of candesartan on CCG in JCR:LA-cp rats.	candesartan	82-93	AKT serine/threonine kinase 1	Rattus norvegicus	36-46	
17962624-9	2008	CZ flow in JCR was partially restored by candesartan (0.45 mL/min/g), accompanied by reduction in superoxide and partial restoration of p38 and Akt activation.	candesartan	41-52	AKT serine/threonine kinase 1	Rattus norvegicus	144-147